-
1
-
-
77950307115
-
Treating rheumatoid arthritis to target: recommendations of an international task force
-
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
-
(2010)
Ann Rheum Dis.
, vol.69
, pp. 631-637
-
-
Smolen, J.S.1
Aletaha, D.2
Bijlsma, J.W.3
Breedveld, F.C.4
Boumpas, D.5
Burmester, G.6
-
2
-
-
84893772728
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
-
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
-
(2014)
Ann Rheum Dis.
, vol.73
, pp. 492-509
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
Buch, M.4
Burmester, G.5
Dougados, M.6
-
3
-
-
84893505901
-
Early start and stop of biologics: has the time come?
-
van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has the time come? BMC Med. 2014;12:25.
-
(2014)
BMC Med.
, vol.12
, pp. 25
-
-
Vollenhoven, R.F.1
Nagy, G.2
Tak, P.P.3
-
6
-
-
73349089655
-
Rheumatoid arthritis and smoking: putting the pieces together
-
Baka Z, Buzás E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther. 2009;11:238.
-
(2009)
Arthritis Res Ther.
, vol.11
, pp. 238
-
-
Baka, Z.1
Buzás, E.2
Nagy, G.3
-
7
-
-
84855172814
-
The pathogenesis of rheumatoid arthritis
-
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.
-
(2011)
N Engl J Med.
, vol.365
, pp. 2205-2219
-
-
McInnes, I.B.1
Schett, G.2
-
8
-
-
34249720998
-
Cytokines in the pathogenesis of rheumatoid arthritis
-
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429-42.
-
(2007)
Nat Rev Immunol.
, vol.7
, pp. 429-442
-
-
McInnes, I.B.1
Schett, G.2
-
9
-
-
0032729679
-
Mortality in rheumatoid arthritis: have we made an impact in 4 decades?
-
Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol. 1999;26:2529-33.
-
(1999)
J Rheumatol.
, vol.26
, pp. 2529-2533
-
-
Gabriel, S.E.1
Crowson, C.S.2
O'Fallon, W.M.3
-
10
-
-
33748997948
-
Cytokine networks - towards new therapies for rheumatoid arthritis
-
McInnes IB, Liew FY. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1:31-9.
-
(2005)
Nat Clin Pract Rheumatol.
, vol.1
, pp. 31-39
-
-
McInnes, I.B.1
Liew, F.Y.2
-
11
-
-
84877603562
-
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
-
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72:863-9.
-
(2013)
Ann Rheum Dis.
, vol.72
, pp. 863-869
-
-
Genovese, M.C.1
Durez, P.2
Richards, H.B.3
Supronik, J.4
Dokoupilova, E.5
Mazurov, V.6
-
12
-
-
84895465850
-
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study
-
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014;41:414-21.
-
(2014)
J Rheumatol.
, vol.41
, pp. 414-421
-
-
Genovese, M.C.1
Durez, P.2
Richards, H.B.3
Supronik, J.4
Dokoupilova, E.5
Aelion, J.A.6
-
13
-
-
84880269392
-
How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy
-
Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822-4.
-
(2013)
Nat Med.
, vol.19
, pp. 822-824
-
-
Schett, G.1
Elewaut, D.2
McInnes, I.B.3
Dayer, J.M.4
Neurath, M.F.5
-
14
-
-
0142093231
-
Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention
-
Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21 Suppl 31:S154-7.
-
(2003)
Clin Exp Rheumatol
, vol.21
, pp. S154-S157
-
-
Quinn, M.A.1
Emery, P.2
-
15
-
-
0038005092
-
Understanding the window of opportunity concept in early rheumatoid arthritis
-
Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48:1771-4.
-
(2003)
Arthritis Rheum.
, vol.48
, pp. 1771-1774
-
-
Boers, M.1
-
16
-
-
84868454136
-
Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials
-
Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71:1921-3.
-
(2012)
Ann Rheum Dis.
, vol.71
, pp. 1921-1923
-
-
Raza, K.1
Saber, T.P.2
Kvien, T.K.3
Tak, P.P.4
Gerlag, D.M.5
-
17
-
-
35348822055
-
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
-
Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226-35.
-
(2007)
Arthritis Rheum.
, vol.56
, pp. 3226-3235
-
-
Aletaha, D.1
Funovits, J.2
Keystone, E.C.3
Smolen, J.S.4
-
18
-
-
19944431840
-
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial
-
Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.
-
(2005)
Arthritis Rheum.
, vol.52
, pp. 27-35
-
-
Quinn, M.A.1
Conaghan, P.G.2
O'Connor, P.J.3
Karim, Z.4
Greenstein, A.5
Brown, A.6
-
19
-
-
34547444116
-
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
-
van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56:2129-34.
-
(2007)
Arthritis Rheum.
, vol.56
, pp. 2129-2134
-
-
Bijl, A.E.1
Goekoop-Ruiterman, Y.P.2
Vries-Bouwstra, J.K.3
Wolde, S.4
Han, K.H.5
Krugten, M.V.6
-
20
-
-
79959795633
-
Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
-
van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70:1389-94.
-
(2011)
Ann Rheum Dis.
, vol.70
, pp. 1389-1394
-
-
Broek, M.1
Klarenbeek, N.B.2
Dirven, L.3
Schaardenburg, D.4
Hulsmans, H.M.5
Kerstens, P.J.6
-
21
-
-
84889677643
-
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
-
Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75-85.
-
(2014)
Ann Rheum Dis.
, vol.73
, pp. 75-85
-
-
Nam, J.L.1
Villeneuve, E.2
Hensor, E.M.3
Conaghan, P.G.4
Keen, H.I.5
Buch, M.H.6
-
22
-
-
77954973766
-
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
-
Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286-91.
-
(2010)
Ann Rheum Dis.
, vol.69
, pp. 1286-1291
-
-
Tanaka, Y.1
Takeuchi, T.2
Mimori, T.3
Saito, K.4
Nawata, M.5
Kameda, H.6
-
23
-
-
84892843036
-
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
-
Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321-32.
-
(2014)
Lancet.
, vol.383
, pp. 321-332
-
-
Smolen, J.S.1
Emery, P.2
Fleischmann, R.3
Vollenhoven, R.F.4
Pavelka, K.5
Durez, P.6
-
24
-
-
84877602545
-
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
-
Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844-50.
-
(2013)
Ann Rheum Dis.
, vol.72
, pp. 844-850
-
-
Detert, J.1
Bastian, H.2
Listing, J.3
Weiß, A.4
Wassenberg, S.5
Liebhaber, A.6
-
25
-
-
73349096059
-
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
-
Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429-34.
-
(2009)
Rheumatology (Oxford)
, vol.48
, pp. 1429-1434
-
-
Soubrier, M.1
Puéchal, X.2
Sibilia, J.3
Mariette, X.4
Meyer, O.5
Combe, B.6
-
26
-
-
67449133540
-
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
-
van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914-21.
-
(2009)
Ann Rheum Dis.
, vol.68
, pp. 914-921
-
-
Kooij, S.M.1
Goekoop-Ruiterman, Y.P.2
Vries-Bouwstra, J.K.3
Güler-Yüksel, M.4
Zwinderman, A.H.5
Kerstens, P.J.6
-
27
-
-
79955856735
-
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
-
Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039-46.
-
(2011)
Ann Rheum Dis.
, vol.70
, pp. 1039-1046
-
-
Klarenbeek, N.B.1
Güler-Yüksel, M.2
Kooij, S.M.3
Han, K.H.4
Ronday, H.K.5
Kerstens, P.J.6
-
28
-
-
68049113582
-
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts
-
van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262-71.
-
(2009)
Arthritis Rheum.
, vol.60
, pp. 2262-2271
-
-
Woude, D.1
Young, A.2
Jayakumar, K.3
Mertens, B.J.4
Toes, R.E.5
Heijde, D.6
-
29
-
-
84861471314
-
Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies
-
van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJ, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120-8.
-
(2012)
Rheumatology (Oxford)
, vol.51
, pp. 1120-1128
-
-
Woude, D.1
Visser, K.2
Klarenbeek, N.B.3
Ronday, H.K.4
Peeters, A.J.5
Kerstens, P.J.6
-
30
-
-
84899902632
-
A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial
-
Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73:1027-36.
-
(2014)
Ann Rheum Dis.
, vol.73
, pp. 1027-1036
-
-
Nam, J.L.1
Villeneuve, E.2
Hensor, E.M.3
Wakefield, R.J.4
Conaghan, P.G.5
Green, M.J.6
-
31
-
-
84918511578
-
Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: The Prize Study
-
Emery P, Spieler W, Stopinska-Polaszewska M, Korshunov NI, Bukowski J, Pedersen R, et al. Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: The Prize Study. Arthritis Rheum. 2013;65(10):2689.
-
(2013)
Arthritis Rheum
, vol.65
, Issue.10
, pp. 2689
-
-
Emery, P.1
Spieler, W.2
Stopinska-Polaszewska, M.3
Korshunov, N.I.4
Bukowski, J.5
Pedersen, R.6
Williams, T.7
-
32
-
-
84918571233
-
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
-
Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-206106 .
-
(2014)
Ann Rheum Dis
-
-
Emery, P.1
Burmester, G.R.2
Bykerk, V.P.3
Combe, B.G.4
Furst, D.E.5
Barré, E.6
-
33
-
-
84917726540
-
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
-
Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-205752 .
-
(2014)
Ann Rheum Dis
-
-
Huizinga, T.W.1
Conaghan, P.G.2
Martin-Mola, E.3
Schett, G.4
Amital, H.5
Xavier, R.M.6
-
34
-
-
84897569032
-
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
-
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24:17-25.
-
(2014)
Mod Rheumatol.
, vol.24
, pp. 17-25
-
-
Nishimoto, N.1
Amano, K.2
Hirabayashi, Y.3
Horiuchi, T.4
Ishii, T.5
Iwahashi, M.6
-
35
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
-
(1988)
Arthritis Rheum.
, vol.31
, pp. 315-324
-
-
Arnett, F.C.1
Edworthy, S.M.2
Bloch, D.A.3
McShane, D.J.4
Fries, J.F.5
Cooper, N.S.6
|